4D Molecular Therapeutics FDMT Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options And Vesting Of Restricted Stock Units
Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options And Vesting Of Restricted Stock Units at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept fdmt:ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsAndVestingOfRestrictedStockUnits.
The official record: 4D Molecular Therapeutics’s 10-K, filed March 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's proceeds from issuance of common stock upon exercise of stock options and vesting of restricted stock units.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's proceeds from issuance of common stock upon exercise of stock options and vesting of restricted stock units?
- 4D Molecular Therapeutics (FDMT) reported proceeds from issuance of common stock upon exercise of stock options and vesting of restricted stock units of $246K in Q4 2025.
- How has 4D Molecular Therapeutics's proceeds from issuance of common stock upon exercise of stock options and vesting of restricted stock units changed year-over-year?
- 4D Molecular Therapeutics's proceeds from issuance of common stock upon exercise of stock options and vesting of restricted stock units decreased by 78.5% year-over-year, from $1.15M to $246K.
- What does proceeds from issuance of common stock upon exercise of stock options and vesting of restricted stock units mean?
- Captures the cash inflows generated from the exercise of employee stock options and the vesting of restricted stock units by personnel. This metric reflects the liquidity provided to the company through the conversion of equity-based compensation awards into common shares. It serves as a source of capital that aligns employee interests with shareholder value.